BrainsWay Expands Mental Health Treatment Across the U.S.
BrainsWay Ltd. (NASDAQ: BWAY), a leader in noninvasive neurostimulation therapies, has reached an exciting milestone with a bold expansion of its Deep TMS™ platform along the East Coast. This move was announced alongside an order for 14 new Deep TMS systems placed by a major enterprise network that specializes in mental health care. This order highlights BrainsWay's growing reputation and reinforces its status as a preferred provider for health practitioners.
CEO Speaks on Expansion Strategy
“We’re excited to broaden access to Deep TMS therapy throughout the East Coast,” said Hadar Levy, BrainsWay’s Chief Executive Officer. The recent order underlines their strong dedication to bringing state-of-the-art treatment options that will help patients. Levy emphasized that building relationships with various mental health organizations is essential for long-term success.
Current Success and Installed Base
As of mid-2024, BrainsWay has over 1,200 Deep TMS systems installed in numerous locations. This wide-ranging network illustrates the effectiveness and acceptance of this innovative treatment approach in tackling complex mental health issues.
About Deep TMS Therapy
Deep Transcranial Magnetic Stimulation (Deep TMS™) is a revolutionary method for treating mental health disorders like major depressive disorder, obsessive-compulsive disorder, and smoking addiction. BrainsWay is recognized as the first company in the TMS field to receive FDA clearance for multiple conditions, supported by comprehensive clinical research demonstrating its effectiveness. The technology employs magnetic fields to stimulate specific areas of the brain, providing hope to patients in search of alternative therapies.
Ongoing Commitment to Research and Development
BrainsWay is dedicated to pushing the boundaries of neurostimulation science. The company is actively involved in clinical trials exploring a variety of psychiatric and neurological conditions. Through these ongoing studies, BrainsWay aims to expand treatment options and reaffirm its leadership position in the neurostimulation landscape.
Increasing Awareness and Access
Established in 2003 and with headquarters in Burlington, MA, and Jerusalem, Israel, BrainsWay continues to strive for greater global awareness around Deep TMS therapy. The company aims to make a positive impact on the lives of those facing mental health challenges by ensuring wider access to their innovative treatment.
Engagement with Investors and Stakeholders
The success of BrainsWay is driven by its dedicated team and their ongoing interaction with investors and stakeholders. The company prioritizes transparency and is committed to keeping partners informed about significant developments, including its recent expansion activities.
Frequently Asked Questions
What is Deep TMS therapy?
Deep TMS therapy is a noninvasive treatment method that utilizes magnetic fields to stimulate targeted regions of the brain, primarily designed to address mental health disorders.
How has BrainsWay expanded its reach recently?
BrainsWay has recently expanded its operations in the U.S. by securing a substantial order for 14 Deep TMS systems from an enterprise network dedicated to mental health.
What are the FDA-cleared indications for Deep TMS?
The FDA has approved Deep TMS for several conditions, including major depressive disorder, obsessive-compulsive disorder, and smoking addiction.
Where can I learn more about BrainsWay?
You can visit BrainsWay's official website for the latest updates and information.
How many Deep TMS systems are currently installed?
As of June 30, 2024, BrainsWay has installed over 1,215 Deep TMS systems worldwide.
